Literature DB >> 20197682

Autoimmune response of IgE antibodies to cellular self-antigens in systemic Lupus Erythematosus.

Ajax Mercês Atta1, Mittermayer Barreto Santiago, Fernanda Garcia Guerra, Mariana Menezes Pereira, Maria Luiza B Sousa Atta.   

Abstract

BACKGROUND: Systemic lupus erythematosus (SLE) patients may exhibit high total IgE and antinuclear IgE antibodies (ANA-IgE). Here, we investigated the specificity of ANA-IgE in SLE patients and the involvement of cytokines in this immune response.
METHODS: Sera from 92 SLE patients and 68 healthy controls were evaluated for the presence of antinuclear IgE antibodies by immunoperoxidase with HEp-2,000(R) cells and immunoblotting with IgG-depleted sera. Total IgE, IgE specific to allergens, and serum cytokine levels were determined by ELISA.
RESULTS: Antinuclear IgE antibodies were detected only in SLE patients (29/92, 31.5%). High total IgE was associated with ANA-IgE (p < 0.0001), but was not associated with IgE antibodies to allergens. In the immunoblotting, ANA-IgE reacted with nucleosomes (23/29, 79.3%), dsDNA (14/29, 48.3%), SS-A/Ro (14/29, 48.3%), SS-B/La (2/29, 18.7%), Sm (14/29, 48.3%) and RNP (18/29, 62.1%). Patients with ANA-IgE had very low serum IL-4, less IL-5 than controls (p < 0.05), more IL-10 than seronegative patients (p < 0.05), and unaltered IFN-gamma levels. The IL-5/IL-10 ratio was lower in ANA-IgE seropositive patients in comparison with either seronegative patients (p < 0.05) or healthy controls (p = 0.001). Controls displayed higher IL-5/IFN-gamma ratios than either SLE patients with ANA-IgE (p < 0.05) or patients without these immunoglobulins (p < 0.01).
CONCLUSIONS: We conclude that IgE antibodies against cell autoantigens involved in protein expression, cellular proliferation, and cell death are present in patients with SLE. Interleukin-10 seems to down-regulate this IgE autoimmune response in SLE. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20197682     DOI: 10.1159/000288293

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  22 in total

1.  Lpr-induced systemic autoimmunity is unaffected by mast cell deficiency.

Authors:  Annemarie Em van Nieuwenhuijze; Bénédicte Cauwe; Denise Klatt; Stéphanie Humblet-Baron; Adrian Liston
Journal:  Immunol Cell Biol       Date:  2015-04-07       Impact factor: 5.126

2.  Activated basophils give lupus a booster shot.

Authors:  Anne Davidson; Betty Diamond
Journal:  Nat Med       Date:  2010-06       Impact factor: 53.440

3.  Polarization toward Th1-type response in active, but not in inactive, lupus inhibits late allergic rhinitis in lupus-prone female NZB×NZWF(1) mice.

Authors:  Toshiharu Hayashi; Ayumi Murase
Journal:  Inflammation       Date:  2012-12       Impact factor: 4.092

4.  IgE-Mediated Immune Response and Antibody-Mediated Rejection.

Authors:  Federica Rascio; Paola Pontrelli; Giuseppe Stefano Netti; Elisabetta Manno; Barbara Infante; Simona Simone; Giuseppe Castellano; Elena Ranieri; Michela Seveso; Emanuele Cozzi; Loreto Gesualdo; Giovanni Stallone; Giuseppe Grandaliano
Journal:  Clin J Am Soc Nephrol       Date:  2020-09-09       Impact factor: 8.237

Review 5.  Basophils, IgE, and autoantibody-mediated kidney disease.

Authors:  Xavier Bosch; Francisco Lozano; Ricard Cervera; Manuel Ramos-Casals; Booki Min
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

6.  Assessment of a high-avidity IgG ANAs for the diagnosis and activity prediction of systemic lupus erythematosus.

Authors:  Yanli Zeng; Yiqiang Lin; Xuelian Wang; Yan Zhang; Feng Peng; JiaJia Wang; Longcan Jiang; Shiqiong Liang; Yun Xiao
Journal:  Clin Rheumatol       Date:  2020-03-18       Impact factor: 2.980

Review 7.  Rethinking the role of immunoglobulin E and its high-affinity receptor: new insights into allergy and beyond.

Authors:  Barbara Dema; Ryo Suzuki; Juan Rivera
Journal:  Int Arch Allergy Immunol       Date:  2014-09-09       Impact factor: 2.749

Review 8.  The pathogenesis of systemic lupus erythematosus-an update.

Authors:  Jinyoung Choi; Sang Taek Kim; Joe Craft
Journal:  Curr Opin Immunol       Date:  2012-11-03       Impact factor: 7.486

9.  Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus.

Authors:  Sarfaraz Hasni; Sarthak Gupta; Michael Davis; Elaine Poncio; Yenealem Temesgen-Oyelakin; Elizabeth Joyal; Alice Fike; Zerai Manna; Sungyoung Auh; Yinghui Shi; Diana Chan; Philip Carlucci; Ann Biehl; Barbara Dema; Nicolas Charles; James E Balow; Meryl Waldman; Richard M Siegel; Mariana J Kaplan; Juan Rivera
Journal:  Arthritis Rheumatol       Date:  2019-05-08       Impact factor: 10.995

10.  Increased IgE serum levels are unrelated to allergic and parasitic diseases in patients with juvenile systemic lupus erythematosus.

Authors:  Bernadete L Liphaus; Adriana A Jesus; Clovis A Silva; Antonio Coutinho; Magda Carneiro-Sampaio
Journal:  Clinics (Sao Paulo)       Date:  2012-11       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.